A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent
study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of
zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.